Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent

Phase 4 Completed 220 enrolled CardioVascular Research Foundation Novartis · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-converting enzyme receptor blockers (ARBs) reduce the risk of restenosis after DES implantation.

Timeline

Start: 2006-09
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Valsartan	Small molecule	160 mg	—

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent

Summary

Timeline

Drugs

Indications